Dyslipidemia management update: LDL targets, ApoB, statin intensity, FH, and pipeline agents
A GP-facing summary of recent lipid-guideline thinking — non-fasting panels, LDL vs ApoB/non-HDL, primary vs secondary prevention targets (including LDL <1.4 after events), statin intensity and adherence, familial hypercholesterolemia flags, PCSK9 options, and triglyceride caveats — from an interventional cardiologist’s seminar talk.
- Primary speaker
- Interventional cardiologist — chair introduction: Dr Max Maffey; speaker self-introduction: Max Mack. Treat both as Otter ASR variants of the same presenter. Closing applause said “Dr Matthew” (likely another ASR slip). Focus: dyslipidemia for GPs after recent guidelines.
- Session context
- Otter id
BDy6sIHW0hMvda56NOIj9eGiImI· title Dyslipidemia Management Update · ~36 min. Distinct from the earlier allcpd dyslipidemia page (different source; no otter_id on that entry).
Key messages for GPs
- LDL remains the primary lipid number with a strong linear link to events; non-fasting panels are fine for most patients.
- If triglycerides >~4.5, calculated LDL fails — request a measured LDL.
- ApoB / non-HDL matter when particles are cholesterol-depleted (diabetes, ASCVD, high TG).
- Secondary prevention target in the talk: LDL <1.4 (tighter than older <1.8), backed by recent intensive-target evidence cited from NEJM-year data.
- Intermediate risk: use modifiers (inflammation, Lp(a), TG, LDL 4.1–4.9) and often start a moderate-intensity statin aiming ~30–40% LDL reduction and LDL <2.6.
- LDL ~5 / ≥4.9 → think FH and refer for opinion.
- Australian adherence is poor (~24% non-adherent by 6 months; ~50% by 5 years in cited secondary-prevention figures).
- Fibrates lower TG but lack clear CV outcome benefit in the framing given; prefer fenofibrate over gemfibrozil with statins; OTC fish oil was discouraged as unreliable.
The lipid panel — fasting and LDL
Non-fasting lipids suit most patients; fasting vs non-fasting LDL give nearly identical prognostic information. Fasting still helps when triglycerides are high. Above ~4.5 mmol/L TG, equations break — ask for measured LDL. LDL retains the strongest trial-linked role among routine lipids.
Do not delay risk assessment because someone “won’t fast.” Order a non-fasting panel, then refine if TG are high.
ApoB and non-HDL residual risk
In diabetes, atherosclerotic disease, and hypertriglyceridaemia, cholesterol-depleted LDL particles can be atherogenic yet under-counted by LDL-C. Residual risk patterns: high ApoB/non-HDL despite “okay” LDL is concerning; the reverse (high LDL but low ApoB/non-HDL) looked more benign in the residual-risk study discussed.
Who to treat — risk tiers
High-risk and secondary-prevention patients need assertive therapy. Intermediate risk is shared decision-making plus modifiers the calculator misses: chronic inflammatory disease (e.g. lupus, RA, psoriasis), high lipoprotein(a), raised TG, persistent LDL ~4.1–4.9. For intermediate-risk starters the talk favoured a moderate-intensity statin, ~30–40% LDL reduction, LDL <2.6 and matching non-HDL goals.
Statin intensity and diabetes signal
Only a short list of regimens qualify as true high-intensity therapy — the speaker walked through low/moderate/high definitions (exact drug list abbreviated here; check current guidelines). Statins can worsen glucose tolerance and uncover diabetes diagnoses; discuss the trade-off honestly while prioritising CV risk reduction when indicated.
Familial hypercholesterolemia flags
Before assuming pure genetics, check thyroid function, urine for nephrotic clues, and medications. Still: LDL around 5 or ≥4.9 enters possible FH territory — high lifetime risk — and referral for cardiology/lipid opinion is reasonable.
Secondary prevention — LDL <1.4
After MI, stent, or stroke, target LDL <1.4. A recent study comparing <1.4 vs <1.8 in ~3000 people with established ASCVD showed fewer events with the intensive target. Pathway: high-intensity statin first, then escalate (ezetimibe, then PCSK9 pathway agents where eligible).
PCSK9 pathway and pipeline
Injectable PCSK9 antibodies and emerging oral options were compared for LDL and Lp(a) effects. A CRISPR-style base-editing single-infusion PCSK9 approach (early study: large LDL drops sustained to 18 months in a small FH/premature CAD cohort) was framed as future-facing — “like a vaccination for heart disease,” not today’s routine tool. Antisense lipoprotein(a)-lowering with ~80% Lp(a) reductions and phase 3 outcome trials was flagged as watch-this-space. PBS criteria for current agents are narrow — confirm eligibility before promising access.
Gene-editing and antisense agents described are educational context from the talk. Do not prescribe or promise them outside approved Australian pathways.
Triglycerides and fibrates
Fenofibrate was preferred; gemfibrozil has more statin interaction risk (rhabdomyolysis case vignette with statin + antifungal). Fibrates can cut TG ~30–50% but were framed as lacking CV outcome benefit. OTC fish oil: variable EPA/DHA content — not recommended as a serious LDL/TG outcome strategy in the talk.
Adherence reality check
“Change your diet, you’ll be fine” does not fix secondary-prevention or FH-level lipids. Australian non-adherence cited: ~24% by six months and ~50% by five years in secondary prevention. Expect and plan for persistence conversations.
- Dyslipidemia — earlier companion lipid page
- AF ablation update
- Cardiovascular and diabetes
- Pharmacogenomics — SLCO1B1 / statin pathway context